secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xtant Medical Holdings, Inc. (XTNT)
CIK:        0001453593
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001493152-23-015373
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xtant Medical Q1 revenue up 38% to $17.9M; initiates FY2023 guidance $73-75M
----------------------------------------------------------------------------

- Q1 2023 revenue of $17.9M, up 38% YoY (29% organic, 9% from Coflex acquisition).
- GAAP net loss improved to $2.1M ($0.02/shr) vs $2.2M ($0.03) in prior year.
- Non-GAAP adjusted EBITDA loss narrowed to $0.3M from $0.9M in Q1 2022.
- Full-year 2023 revenue guidance of $73M-$75M, representing 26%-29% annual growth.
- Gross margin expanded to 58.7% from 58.3%, driven by Coflex contribution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453593/000149315223015373/0001493152-23-015373-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453593/000149315223015373/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-015373

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer